We have identi®ed a novel protein, BAP1, which binds to the RING ®nger domain of the Breast/Ovarian Cancer Susceptibility Gene product, BRCA1. BAP1 is a nuclearlocalized, ubiquitin carboxy-terminal hydrolase, suggesting that deubiquitinating enzymes may play a role in BRCA1 function. BAP1 binds to the wild-type BRCA1-RING ®nger, but not to germline mutants of the BRCA1-RING ®nger found in breast cancer kindreds. BAP1 and BRCA1 are temporally and spatially coexpressed during murine breast development and remodeling, and show overlapping patterns of subnuclear distribution. BAP1 resides on human chromosome 3p21.3; intragenic homozgyous rearrangements and deletions of BAP1 have been found in lung carcinoma cell lines. BAP1 enhances BRCA1-mediated inhibition of breast cancer cell growth and is the ®rst nuclearlocalized ubiquitin carboxy-terminal hydrolase to be identi®ed. BAP1 may be a new tumor suppressor gene which functions in the BRCA1 growth control pathway.
Introduction
The cloning of the chromosome 17q21 BRCA1 breast cancer susceptibility gene is a landmark accomplishment in cancer genetics . Germline mutations in BRCA1 appear to account for *50% of familial breast cancers and essentially all families with 17q21-linked inherited susceptibility to ovarian and breast cancer (Szabo and King, 1995) . The importance of this gene is underscored by the fact that kindreds segregating constitutional BRCA1 mutations show a lifetime risk of 40 ± 50% for ovarian cancer and 480% for breast cancer (Easton et al., 1993 (Easton et al., , 1995 . The classi®cation of BRCA1 as a highly penetrant, autosomal dominant tumor suppressor gene has been genetically con®rmed by the ®nding of frequent LOH of the wild-type allele in breast tumors from mutation carriers (Hall et al., 1990; Miki et al., 1994; Smith et al., 1992) . Surprisingly, BRCA1 mutations in sporadic breast cancer, including those which show 17 g LOH, have yet to be found and BRCA1 mutations are extremely rare in sporadic ovarian cancer Merajver et al., 1995) .
The BRCA1 locus spans 4100 kb comprising 24 exons . More than 100 constitutional mutations have been identi®ed in BRCA1 over the entire length of the gene. Some clustering of these mutations has been seen in populations, and genotypephenotype correlations have been suggested (FitzGerald et al., 1996; Ford et al., 1994; Muto et al., 1996; Roa et al., 1996; Struewing et al., 1995) . The majority of germline mutations result in a truncated BRCA1 protein although recurrent missense mutations resulting in amino acid substitutions in kindreds have also been observed (Couch and Weber, 1996) . The heterogeneity of BRCA1 mutant proteins produced by this spectrum of genetic mutations suggests that multiple, independent functions and/or protein ± protein interaction surfaces are targets for mutational inactivation. However, the biochemical functions of BRCA1 are largely unknown.
The predominant BRCA1 mRNA of 8.0 kb encodes a 1863 amino acid protein with only a few sequence motifs suggestive of function . There are two highly conserved regions. The ®rst is the 100 amino acid N-terminus which encodes a RING ®nger motif, a domain that is predicted to bind zinc and may be a protein ± protein interaction motif (Borden et al., 1995; Lovering et al., 1993) . The second region is at the C-terminus which contains an acidic region and two copies of a novel motif, designated the BRCT domain. The BRCT domain is present in a variety of putative cell-cycle related proteins, including RAD9 and 53BP1 (Koonin et al., 1996) . The most abundant BRCA1 protein is apparently a *220 kDa phosphoprotein which is predominantly, but apparently not exclusively, nuclear in subcellular distribution Scully et al., 1996) . BRCA1 is localized to discrete nuclear dot structures in a cell-cycle-dependent manner (Scully et al., 1997b) . Other isoforms of BRCA1 have been detected including a protein of 97 kDa. This smaller form lacks exon 11, and thus a functional nuclear localization signal, and is presumably the result of an alternative splicing event (Thakur et al., 1997) . The above observations, coupled with the ®nding of a BRCA1 COOH-terminal domain capable of activating transcription as a Gal4 DNA-binding domain fusion (Chapman and Verma, 1996) and the co-fractionation of BRCA1 with the RNA pol II holoenzyme (Scully et al., 1997a) , suggest a role for BRCA1 in transcriptional regulation.
The expression patterns of BRCA1 further support its role in growth regulation and/or dierentiation. The spatial-temporal expression pattern in the embryonic mouse includes the neuroepithelium, and epithelial lineages of the skin, kidney and mammary gland (Marquis et al., 1995) . Moreover, BRCA1 mRNA is sharply increased in alveolar and ductal cells of the breast epithelia during pregnancy (Marquis et al., 1995) . Consistent with this, BRCA1 transcription is under (indirect) hormonal control in both cell culture and organismal systems (Gudas et al., 1995 (Gudas et al., , 1996 Vaughn et al., 1996; Marks et al., 1997) . BRCA1 is also highly expressed in the adult testis during the ®nal stages of meiosis and spermiogenesis (Zabludo et al., 1996) . Together, these observations suggest a broad role for BRCA1 in terminal dierentiation events in multiple tissues. Somewhat paradoxically, the murine brca17/7 embryos die very early in gestation and exhibit severe cell proliferation defects and profound cell cycle arrest (Hakem et al., 1996; Liu et al., 1996) . The association of BRCA1 expression with both proliferation and dierentiation events suggests a possible role for BRCA1 in regulating a genetic program which prepares the cell for terminal differentiation and possibly maintains that phenotype. Results of cell culture and transfection studies have underscored the tumor suppression function of BRCA1, but have revealed little of possible mechanisms. BRCA1 antisense expression can transform ®broblasts and accelerates growth of breast cancer cell lines (Rao et al., 1996; Thompson et al., 1995) . Expression of wild-type BRCA1 inhibits colony formation and tumor growth in vivo, whereas tumor derived mutants of BRCA1 lack this growth suppression activity (Holt et al., 1996) .
Evidence of a role for BRCA1 as a terminal dierentiation checkpoint has recently been provided by the ®nding that BRCA1 and the RAD51 protein (involved in DNA recombination/repair) are colocalized and physically associated in mitotic and meiotic cells (Scully et al., 1997b) . The co-localization of BRCA1 and RAD51 on synaptonemal meiotic chromosomes suggests a role for this complex in either the ®delity of DNA replication, cell-cycle progression or genomic integrity. Though intriguing, these results do not suggest a function for BRCA1 which, when lost through mutation of the BRCA1 gene, would give rise to tumors. Strategies based upon identi®cation of proteins which bind to BRCA1 have yielded components of the nuclear import pathway and a novel RING ®nger/BRCTdomain-containing protein, BARD1 (Jin et al., 1997; Wu et al., 1996) . However, none of these associated proteins have suggested a function for BRCA1.
We have chosen to focus upon the highly conserved BRCA1 RING ®nger domain as a potential protein ± protein interface. This motif is de®ned by a spatially conserved set of cysteine ± histidine residues of the form C 3 HC 4 . Structural analysis of the motif shows that two molecules of zinc are chelated by the consensus residues in a unique`cross-braced' fashion (for reviews, see; Klug and Schwabe, 1995; Saurin et al., 1996) . Comparative structure analyses suggest that the RING ®ngers have a common hydrophobic core structure but that the region encoded by amino acids spanning cysteines 24 and 64 (for BRCA1) forms a highly variable loop structure which may be the determinant of protein ± protein interaction speci®city. The RING motif occurs in over 80 proteins including the products of proto-oncogenes and putative transcription factors (Saurin et al., 1996) . Evidence that the RING ®nger domain functions as a protein ± protein interface has come from the study of the protooncogene PML (Borden et al., 1995) and the transcriptional co-repressor KAP-1 (Friedman et al., 1996) . Intriguingly, like BRCA1, both PML and KAP-1 are localized to discrete, non-overlapping, nuclear dot structures, and mutations in the RING ®nger of PML abolish its localization to these dot structures (Borden et al., 1995) .
We hypothesize that the BRCA1 RING ®nger is a binding site for protein(s) which either mediate BRCA1 tumor suppressor function or serve to regulate these functions. Genetic evidence supports this in that single amino-acid substitutions at metal chelating cysteines, C61G and C64G, occur in BRCA1 kindreds; these mutations segregate with the disease susceptibility phenotype and are predicted to abolish RING ®nger structure. We have used the yeast two-hybrid system to isolate proteins which bind to the wild-type BRCA1 RING ®nger but not to the C61G or C64G mutated RING ®ngers or other closely related RING ®ngers. We have isolated mouse and human clones of a novel protein, BRCA1 associated protein-1 (BAP), which ful®ls these criteria. BAP1 is a novel, nuclear-localized enzyme which displays the signature motifs and activities of a ubiquitin carboxy-terminal hydrolase. Full-length BRCA1 binds to BAP1 in vitro and enhances the growth suppression properties of BRCA1 in colony formation assays. The human BAP1 locus was mapped to chromosome 3p21.3, and homozygous deletions of BAP1 were found in nonsmall cell lung cancers. Together, these data suggest that BAP1 is a key player in the BRCA1 growth suppression pathway, and may itself be a tumor suppressor gene. The identi®cation of BAP1 as a ubiquitin hydrolase implicates the ubiquitin-proteasome pathway in either the regulation, or as a direct eector, of BRCA1 function. BAP1 is the ®rst nuclearlocalized ubiquitin carboxy-terminal hydrolase to be identi®ed, and may play a broad role in ubiquitindependent regulatory processes within the nucleus, including the emerging roles of ubiquitin conjugation as a post-translational modi®cation which alters protein function and/or subcellular targeting.
Results

A yeast two-hybrid screen for BRCA1 RING ®nger interacting proteins
We constructed a synthetic BRCA1 gene encoding the amino-terminal 100 amino acids of human BRCA1 using long oligonucleotides and PCR-mediated over-lap-extension gene synthesis techniques (Madden et al., 1991) . Codon usage was optimized for expression in E. coli and S. cerevisiae. The resulting gene was fused to the LexA DNA binding domain (Figure 1b) . The negative control/speci®city controls included: (1) the Cys61Gly, Cys64Gly, Met18Thr and Arg71Gly muta-
Figure 1 BRCA1 RING ®nger domain binds a novel protein.
(a) Alignment of the RING ®nger domains of human and mouse BRCA1 (AA's 21 ± 67), RPT-1 (AA's 12 ± 61; the most closely related RING ®nger) and BARD1 (AA's 47 ± 89). Asterisks (*) identify the Zn-chelating amino acids that form the core of the RING ®nger. Boxed amino acids show regions of identity between the RING ®nger domains of human BRCA1 and the other proteins. Alignment performed by CLUSTALW (Thompson et al., 1994) . (b) The amino-terminal 100 amino acids of human BRCA1 (which includes the RING ®nger domain) or the indicated amino acids of the various BRCA1 ± RF mutants and controls were fused to the LexA DNA-binding domain. Expression of all fusions in yeast was con®rmed by Western analysis. A summary of the two-hybrid interaction between the Gal4-hBAP1(483 ± 729) fusion clone and the various LexA-RING ®nger fusions is shown. (c) The BRCA1-interacting protein speci®cally interacts with the BRCA1 RING ®nger domain. Two hybrid screens of a human B-cell library and a mouse embryo (9.5 ± 10.5 days) library identi®ed a protein that interacted with wild type BRCA1 ± RF, but not with BRCA1-del31 (a truncated BRCA1), BRCA1(Cys64Gly) (a BRCA1 ± RF containing a point mutation), RPT-1 (a RING ®nger closely resembling the BRCA1), or RhoB (a non-related protein). tions that occur in BRCA1 families; (2) the protein equivalent of the del AG185 mutation which results in a frame-shift at amino acid 22 followed by 17 out-offrame amino acids and a stop codon; (3) a truncated BRCA1 RING ®nger at amino acid 31, the result of a PCR error; (4) the RPT-1 RING ®nger domain, a putative lymphocyte-speci®c transcription factor, whose RING ®nger domain is most highly related to Figure 2 BAP1 is a novel ubiquitin carboxy-terminal hydrolase (UCH). (a) The nucleotide and amino acid sequence of BAP1. The longest open reading frame which contained the amino acids de®ned by the human 2-hybrid fusion protein is 2188 nucleotides encoding 729 amino acids. The cDNA also contains 39 nucleotides of 5'UTR and 1295 nucleotides of 3'UTR. The enzymatic active site is contained within the ®rst 250 amino acids; the active site residues are circled. The putative nuclear localization signals (NLS) are underlined, the BRCA1-interaction domain is boxed and the protein fragment used to generate BAP1 polyclonal antibodies is bracketed (AAs 483 ± 576). (b) Comparison of BAP1 with other UCH's. UCH DROME (genebank #P35122), YUH1 (genebank #P35127), UCHL-1 (genebank #PO9936), UCHL-3 (genebank #P15374), UCH A.cal. (genebank #U90177). The BLAST search algorithm was used to identify proteins closely related to BAP1 (Altschul et al., 1990) . The UCH domain of ®ve of these proteins were aligned with BAP1 using the CLUSTALW (ver.1.6) algorithm (Thompson et al., 1994) . Residues conserved between species with an identity of 85% or greater are boxed. Active site residues are denoted with asterisks. Guided by the expression patterns of BRCA1 during mouse development and in human spleen, we chose to screen cDNA libraries constructed from E9.5-10.5d whole mouse embryos and human adult B cells with the LexA-BRCA1 ± RF. Thirty-one cDNAs which speci®cally interacted with BRCA ± RF were obtained: eight of these (three from the human library and ®ve from the mouse library) encoded the same amino acid sequence. These were designated BRCA1 Associated Protein-1 (BAP1) and pursued further. Each clone shares the same translational reading frame with respect to the transcriptional activation domain to which it is fused. In addition, the fusion junctions were dierent among the clones, suggesting that the interaction was not due to a fusion-junction artifact. Furthermore, the hBAP1 (483 ± 729) and the BRCA1 ± RF interacted strongly in a mammalian two-hybrid assay (data not shown). The longest BAP1 cDNA retrieved in the two-hybrid screen was a *2.0 kbp clone from the human library and encoded 246 amino acids followed by a 1.3 kb 3'UTR. Each murine clone encoded an overlapping, smaller subset of this human open reading frame with a human-murine AA sequence identity of 100% over the COOH-terminal 100 AAs (data not shown). Both human and mouse clones showed a strong interaction with the wild-type BRCA1 ± RF and BRCA1 (Arg71Gly) substitution, but failed to interact with the C64G, C61G, del31, delAG, RPT-1, RhoB, or a variety of other LexA fusion constructs (Figure 1b,c and data not shown).
Further de®nition of this highly conserved interaction domain was performed by mutagenesis of this region of BAP1. Deletion of protein sequence from the carboxyl or amino termini of mBAP1(596 ± 721) almost completely destroyed the BAP1-BRCA1 interaction (Figure 1d ), possibly suggesting an extended interface between the proteins. Interestingly, the mBAP1(518del718) clone interacted most poorly with BRCA1 ± RF ( Figure 1c ) and lacked a 93 bp sequence (the reading frame was maintained), possibly the result of a naturally occurring splice variant. That BAP1 also failed to bind multiple, independent tumor-derived mutations of the BRCA1 ± RF provides strong evidence for the relevance of this interaction to the functions of BRCA1.
Analysis of the BAP1 cDNA
A full-length cDNA was constructed using two IMAGE consortium EST clones and RT ± PCR (Figure 2a ; see Materials and methods). The BAP1 cDNA comprises 3525 bp; a polyA tract is present along with multiple polyA signals. Conceptual translation yields a long open reading frame of 729 amino acids with a predicted MW of 81 kDa and pl of 6.3. The presumptive initiator methionine is within a favorable context for translation start, however the short 5'UTR of 39 bp encodes amino acids in-frame with the presumptive methionine and does not contain a stop codon. Computer database searches indicated that BAP1 is a novel protein with the amino-terminal 240 amino acids showing signi®cant homology to a class of thiol proteases, designated ubiquitin C-terminal hydrolases (UCH), which are implicated in the proteolytic processing of ubiquitin . These enzymes play a key role in protein degradation via the ubiquitin-dependent proteasome pathway. Similarities to other mammalian UCHs (UCH-L3 and UCH-L1) have been found (Figure 2b and c). Most importantly, the residues which form the catalytic site (Q85, C91, H169 and D184) are completely conserved, including the FELDG motif (Larsen et al., 1996) . In addition, a loop of highly variable sequence, which is disordered in the crystallographic structure of human UCH-L3 (Johnston et al., 1997) , is present (residues 140 ± 167). This loop may occlude the active site or provide substrates speci®city for the enzyme.
BAP1 has a number of additional motifs; a region of extreme acidity spanning amino acids 396 to 408, as well as multiple potential phosphorylation sites and Nlinked glycosylation sites ( Figure 2a ). The C-terminal one-third is highly charged and is rich in proline, serine and threonine. The extreme C-terminus contains two putative nuclear localization signals, KRKKFK and RRKRSR and is hydrophilic, it is predicted to fold into a helical (possibly coiled-coil) structure (Figure 2a ; ---BRCA1-∆11 BAP1
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c Figure 4 BAP1 and BRCA1 interact in vitro and in vivo. (a) BRCA1 and GST-hBAP1(483 ± 729) interact in vitro. GST, GSThBAP1(483 ± 729) and GST-hBAP1(483 ± 594) fusion proteins were expressed in E. coli and puri®ed as described in Materials and methods. The Glutathione-Sepharose resins, containing an equivalent amount of fusion protein, were incubated in batch with in vitro-expressed, 35 S-labeled, BRCA1. After extensive washing, the proteins which remained bound were analysed by SDS ± PAGE and¯uorography. Lane 1, Input 2% of the labeled BRCA1 used in the associations with the glutathione resins. Lane 2, molecular weight markers. Lane 3, proteins bound to GST alone. Lane 4, proteins bound to GST-hBAP-1(483 ± 729). Lane 5, proteins bound to GST-hBAP1-(483 ± 594), a fusion protein lacking the BRCA1-interaction domain. Arrow indicates the BRCA1 protein. (b) Coimmunoprecipitation of BRCA1-D11 and BAP1. COS1 cells, transiently transfected with BRCA1-D11, BAP1, or BRCA1-D11 and BAP1 together, were treated with DMSO (7) or with 25 mM ALLN (+) for 16 h. Whole cell extracts were prepared after metabolic labeling and then immunoprecipitated with anti-BAP1 antibody (BAP1) or with anti-BRCA1 antibody, C20 (BRCA1) as indicated. Immunoprecipitated proteins were visualized by SDS ± PAGE and¯uorography. The BAP1 and BRCA1-D11 proteins are indicated. (c) BRCA1 and BAP1 partially co-localize in the nucleus. Asynchronous Rh30 cells were co-stained with the BRCA1-speci®c BR64 monoclonal antibody (green, top and bottom panels; Upstate Biotechnology) and a BAP1 speci®c, anity-puri®ed polyclonal antibody (red, middle and bottom panels). Top and middle panels are single color readouts of the dual color bottom panel. Yellow is produced where green and red images overlap S Subbiah, personal communication). Indeed, within this domain the mutation of leucine 691 to a proline, a change predicted to disrupt the helical nature of this region, abolished the BAP1 ± BRCA1 interaction (Figure 1d ). This result is consistent with the hypothesis that BAP1 uses a coiled-coil domain to interact with the RING ®nger domain of BRCA1. This overall architecture suggests that BAP1 is a new, structurally complex, nuclear-localized member of the UCH enzyme family.
BAP1 has UCH activity
To determine whether BAP1 did indeed have UCH enzymatic activity, BAP1 was expressed in bacteria and this protein was assayed for the ability to hydrolyze the glycine 76 ethyl ester of ubiquitin (Ub-OEt; Mayer and . IPTG-induced expression of BAP1 in bacteria led to abundant protein, most of which was found in an inactive, insoluble form (Figure 3a ,`BAP1 induced-Ppt'). The BAP1 protein found in the soluble + RNA isolated from mouse mammary glands at the indicated developmental stages was probed with 32 P-labeled mBAP1(596 ± 721) cDNA. Note that mouse Bap1 RNA is slightly smaller than the human BAP1 RNA. (c) In situ hybridization analysis of Bap1 expression. Bright-®eld (1, 3, 5, 7, 9 and 11) and dark-®eld (2, 4, 6, 8, 10 and 12) photomicrographs of in situ hybridization analyses performed on paran sections of mammary glands harvested from adolescent (1 ± 4), mature (5, 6) or pregnant (9, 10) mice. Also shown are sections of testis (7, 8) and ovary (11, 12) . To facilitate comparison, dark-®eld photomicrographs of breast were taken using identical shutter exposure times. al, alveolar bud; d, ductal epithelium; lu, ductal lumen; st, stroma; teb, terminal end bud; d, bm, basement membrane; se, semeniferous tubule; f, developing follicle; g, granulosa cells; th, thecal cells; ct, connective tissue fraction was able to hydrolyze Ub-OEt, indicating that BAP1 contains UCH-like enzymatic activity ( Figure  3b ). The active site thiol residue responsible for UCH activity in UCH-L3 has been identi®ed and its mutation leads to abolition of enzyme activity (Larsen et al., 1996) . Mutation of the corresponding cysteine residue in BAP1, BAP1(C91S), yielded a protein with no detectable UCH activity (Figure 3b ) further supporting the conclusion that BAP1 is a thiol protease of the UCH family.
BAP1 associates with BRCA1 in vitro and in vivo Association of BRCA1 with BAP1 was tested in vitro by binding of full-length BRCA1 to hBAP1(483 ± 729) fused to glutathione S-transferase (GST; Figure 4a) . The 35 S-labeled BRCA1, produced by coupled in vitro transcription and translation, speci®cally bound to the GST ± hBAP1(483 ± 729) fusion protein, but not to GST alone (Figure 4a ) indicating a physical association between the two proteins. As predicted from the yeast two-hybrid results (Figures 1d and 4a ), BRCA1 did not bind to GST ± hBAP1(483 ± 594), a GST ± BAP1 fusion protein lacking the BRCA1 interaction domain.
To determine whether BRCA1 and BAP1 could interact in mammalian cells, a co-immunoprecipitation analysis from co-transfected COS1 cells was performed (Figure 4b ). Several attempts to transiently express BRCA1 to any signi®cant level in COS1 cells were without success. Therefore, we performed the analysis with BRCA1-D11, a naturally occurring splice variant (Thakur et al., 1997) which can be expressed in these cells and which contains the RING ®nger domain. The proteasome/caspase inhibitor ALLN (N-acetyl-L-Leucinyl-L-Leucinyl-L-norLeucinal) was included in the analysis to determine its in¯uence on the stability of the interaction between BRCA1 and BAP1. BRCA1-D11 was detected by immunoprecipitation as a sharp band at *99 kDa in singly transfected COS1 cells (Figure 4b, lane 1) . Incubation of a parallel set of transfected cells with ALLN (20 h) prior to harvest revealed a discrete slower migrating band in the anti-BRCA1 immunoprecipitates (Figure 4b, lane 2) . Immunoprecipitates from BAP1-transfected COS1 cells revealed a 91 kDa protein whose mobility was apparently unaected by treatment with ALLN ( Figure  4b, lanes 3 and 4) . Co-transfection of COS1 cells with BRCA1-D11 and BAP1 revealed that these proteins could be co-immunoprecipitated using either anti-BAP1 or anti-BRCA1 antibodies (Figure 4b , lanes 9 and 10); the ability to detect the BRCA1 ± BAP1 complex under these conditions was dependent upon incubation of the cells with the proteasome inhibitor. In co-transfected, ALLN-treated cells, both forms of BRCA1-D11 are evident in the co-immunoprecipitated complex, and both forms are more abundant than singly transfected cells (compare lanes 2 and 10). These results demonstrate the in vivo association of BRCA1 and BAP1, and suggest the presence of a proteasome inhibitor-sensitive modi®cation of BRCA1 which may enhance its interaction with BAP1.
To further document the in vivo interaction between BAP1 and full-length BRCA1, we determined whether the endogenous (non-transfected) proteins were colocalized in the cell nucleus (Figure 4c) . A mouse monoclonal antibody to BRCA1 (Maul et al., manuscript in preparation) and anity puri®ed rabbit BAP1 antibody were used to stain rhabdomyosarcoma cells (Rh30), a cell line previously determined to express BAP1 RNA (Jensen and Rauscher, unpublished results). BRCA1 was detected exclusively in punctate domains within the nucleus (excluding nucleoli) in agreement with other reports (Jin et al., 1997; Scully et al., 1997b) . BAP1 was also detected in punctate domains within the nucleus of Rh30 cells, however, the number of domains was signi®cantly greater than for BRCA1. Several of the BRCA1 domains coincided with BAP1 domains (yellow dots in the bottom panels), suggesting an endogenous BRCA1-BAP1 interaction. We also detected BRCA1 reactive domains which were not co-localized with BAP1 domains as has been seen with other BRCA1-interacting proteins (Figure 4c ; Jin et al., 1997; Scully et al., 1997b) . These data show that BAP1 and BRCA1 can physically interact in vitro and in vivo, and have overlapping subnuclear expression patterns. BAP1 is expressed in a temporal and spatial pattern during breast development/remodeling
The physical interaction between BAP1 and BRCA1 suggests that the proteins might be expressed in similar tissues. Northern blot hybridization analysis of BAP1 expression in a variety of human adult tissues indicated that human BAP1 was encoded by a single mRNA species of *4 kb in all tissues except testis, where a second, *4.8 kb mRNA, was also detected (Figure  5a ). High expression was detected in testis, placenta and ovary, with varying levels detected in the remaining tissues. Expression of BAP1 in normal human breast tissue was detected by RT ± PCR of total RNA isolated from normal human mammary epithelial cells (data not shown).
Northern analysis and in situ hybridization were performed to determine whether the spatial and temporal pattern of Bap1 expression in the breast corresponded to that previously described for Brca1 (Figure 5b and c; Marquis et al., 1995) . Bap1 was expressed at slightly higher levels in the mammary glands of 5 week-old adolescent female mice compared to 15 week-old mature mice. Consistent with this, in situ hybridization revealed high level of Bap1 mRNA expression in terminal end buds (Figure 5c ), and higher levels of Bap1 expression in the ductal epithelium of adolescent as compared with mature female mice. Like Brca1, Bap1 mRNA was expressed in the mammary epithelium at levels higher than those found in the stromal compartment. Steady-state levels of Bap1 mRNA were up-regulated in the mammary glands of pregnant mice (Figure 5b and c) . Like Brca1, in situ hybridization demonstrated that this up-regulation occurred predominantly in developing alveoli ( Figure  5c ). Bap1 was expressed at higher levels in the mammary glands of parous animals that had undergone 28 days of post-lactational regression as compared with age-matched virgin controls (cf. D28 regression and 15 week virgin). The observation that Bap1 expression is up-regulated in the breast during puberty, pregnancy and as a result of parity is similar to that previously made for Brca1 and suggests the developmental co-expression of these two proteins (Marquis et al., 1995) . It should be noted, however, that the magnitude of Bap1 up-regulation at each of these developmental stages was lower than that observed for Brca1. The spatial distribution of Bap1 expression was also investigated in the testis and ovary (Figure 5c ). Like Brca1, Bap1 was expressed at high levels in semeniferous tubules, with lower levels of expression observed in the surrounding connective tissue. Bap1 was also expressed at high levels throughout the ovary.
BAP1 augments the growth suppressive activity of BRCA1
Several studies have shown that BRCA1 can aect the growth characteristics of cells (Holt et al., 1996; Rao et al., 1996) . We determined whether BAP1 itself may aect cell growth or may alter BRCA1-mediated changes in cell growth. BRCA1 and BAP1 cDNAs were co-transfected into MCF7 breast cancer cells and analysed for their eect on colony formation ( Figure  6 ). This cell line was chosen for several reasons: First, it previously has been shown that the growth of these cells is inhibited by the overexpression of BRCA1 (Holt et al., 1996) . Second, both Northern and RT ± PCR analyses showed that BAP1 is expressed in this cell line (data not shown). Finally, RT ± PCR/SSCP analysis of the open reading frame of BAP1 cDNA prepared from this cell line showed no mutations (data not shown).
The expression of BRCA1 alone (BRCA : pCMV5) decreased the number of colonies formed by these cells when compared to the vector control (pcDNA3 : pCMV5), in agreement with other studies (Holt et al., 1996) . The co-expression of BRCA1 and BAP1 (BRCA1 : BAP1) signi®cantly decreased the number of cell colonies (approximately fourfold vs BRCA1 alone; see Figure 6b ) indicating that BAP1 enhances the growth suppressive actions of BRCA1. A mutant of BAP1, BAP1(165 ± 729), in which the enzymatic region is deleted but which still binds to BRCA1, also enhanced the growth suppression of BRCA1, but not to the same extent as the wild-type BAP1.
The expression of BRCA1-D11 (a naturally occurring splice variant of BRCA1) in MCF7 cells by itself had no eect on the growth of MCF7 cells (Figure 6 ). However, the co-expression of BRCA1-D11 and BAP1 dramatically decreased the number of colonies, suggesting that the presence of BAP1 could cooperate with BRCA1-D11 in cell growth inhibition. Furthermore, the expression of BAP1 in MCF7 cells also reduced the number of colonies formed (pcDNA3 : BAP1; see Figure 6b ). The expression of the enzymatic mutant, BAP1(165 ± 729), alone or in combination with BRCA1-D11, yielded no growthsuppression activity. Thus, enzymatically active BAP1 enhances BRCA1-mediated suppression of growth in this assay.
BAP1 is located on chromosome 3p21.3 and is mutated in non-small cell lung carcinoma
The data above suggest the possibility that BAP1 itself may be a tumor suppressor gene and that BAP1 alterations/deletions might play a role in human tumorigenesis. We determined whether BAP1 might be located at a chromosomal region previously observed to be mutated in human cancers. The fulllength BAP1 cDNA was used in¯uorescent in situ hybridization (FISH) to identify the chromosomal location of the BAP1 gene (Figure 7 ). Speci®c signals were observed only on the midportion of the short arm of chromosome 3 with 42 of 69 analysed metaphase spreads showing at least one speci®c signal. The FLpter value was 0.27+0.02 corresponding to a localization for BAP1 at 3p21.2-p21.31. This location is a region of LOH for breast cancer as well as a region frequently deleted in lung carcinomas (Buchhagen et al., 1994; Thiberville et al., 1995) .
The chromosomal location of BAP1 suggested the possibility of mutations within BAP1 in lung tumors. Thus, a total of 44 small cell lung cancer (SCLC), 33 non-small cell lung cancer (NSCLC) and two lymphoblastoid tumor cell lines were screened for mutations within the BAP1 gene by Southern, Northern and PCR-based SSCP analyses. Genomic DNAs from 15 small cell lung cancer (SCLC), 18 non-small cell lung cancer (NSCLC) and two lymphoblastoid cell lines (representing a subset of the total), were subjected to EcoRI digestion and then hybridized to a full-length (Phelps et al., 1996) BAP1 cDNA probe. A single 23 kb band was detected in the lymphoblastoid and most tumor cell lines (data not shown). One NSCLC line, NCI-H226, did not show the 23 kbp band but did show an aberrant 30 kbp band (data not shown). This abnormality was con®rmed by BamHI, XbaI, PstI and BglII digestions. Using the 3.5 kbp BAP1 cDNA probe with BamHI digested genomic DNAs, we detected four distinct bands at 7.5 kbp, 4.0 kbp, 3.0 kbp and 2.4 kbp which were present in all cell lines tested with the exception of NCI ± H226 (a representative subset is shown in Figure  8a ). In the NCI-H226 line, we detected only the 2.4 kbp band and an aberrant 2.6 kbp band.
Further mutational analysis of BAP1 was performed by screening a subset of 31 SCLC and 27 NSCLC lung cancer cell lines and two lymphoblastoid cell lines for expression of BAP1 mRNA. Northern analysis showed that most cell lines expressed a single *4 kb mRNA (Figure 8b) . However, two cell lines, NCI ± H226 and NCI ± H1466 (both NSCLCs), showed undetectable levels of BAP1 expression, suggesting that BAP1 may be a target for inactivation or down-regulation during NSCLC pathogenesis. The absence of BAP1 protein in the NCI ± H226 line was determined by immunoprecipitation of BAP1 from 35 S-labeled cells (Figure 8d ). We screened cDNAs from all 44 SCLC and 33 NSCLC cell lines for mutations in the BAP1 open reading frame by RTPCR ± SSCP (Figure 8c) . A homozygous, eight base pair deletion and a presumed splice variant were detected. An 8 bp deletion was detected in the cDNA from the NSCLC line NCI ± H1466; This short deletion leads to a frameshift/ truncation yielding a predicted 393 amino acid protein. This homozygous deletion was con®rmed in genomic DNA from the same cell line (data not shown). A 54 bp in-frame deletion (nts. 705 ± 758) was detected in the NCI ± H1963 (SCLC) cell line. This deletion was heterozygous at the cDNA level and not present in the genomic DNA, suggesting that it is a splice variant. However, this variant was not detected in any of the other cell lines screened. These data clearly show that genetic alterations, including intragenic homozygous deletions, can occur in BAP1.
Discussion
We have discovered and characterized a novel protein, BAP1, which binds to the BRCA1 RING ®nger motif. Several lines of evidence are oered which support a role for BAP1 in BRCA1 signal transduction pathways. We showed that: (1) BAP1 binds to the RING ®nger of BRCA1; but not to germline mutants of BRCA1 or related RING domains; (2) The BAP1 ± BRCA1 interactions occurs in vitro and in vivo, and these proteins are partially co-localized in nuclear dot structures; (3) BAP1 mRNA is expressed in those tissues which also expresses BRCA1, and the spatial/ temporal distribution of Bap1 expression in the mouse breast is very similar to that observed with Brca1; (4) BAP1 enhances BRCA1-mediated suppression of cell growth in colony formation assays, and suppression by BAP1 is augmented by its UCH enzymatic domain; and (5) BAP1 maps to chromosome 3p21.3 and is homozygously deleted in a lung carcinoma cell line. Together, these observations suggest that BAP1 may be a tumor suppressor gene, and that it may serve as a regulator of (or is an eector for) BRCA1 growth control/dierentiation pathways. The speci®city of the BRCA1 RING ®nger-BAP1 interaction and the fact that independent, germline missense mutations in the BRCA1 RING ®nger domain abolish interaction with BAP1 provide substantial evidence for the physiological relevance of this interaction.
BAP1 is a nuclear-localized, ubiquitin carboxyterminal hydrolase (UCH) which can cleave model ubiquitin substrates in vitro. The UCH homology of BAP1 implies a role for either ubiquitin-mediated, proteasome-dependent degradation or other ubiquitinmediated regulatory (Isaksson et al., 1996) pathways in BRCA1 function. Regulated ubiquitination of proteins and subsequent proteasome-dependent proteolysis plays a role in almost every cellular growth, dierentiation and homeostatic process (reviewed by Ciechanover, 1994; Isaksson et al., 1996; Wilkinson, 1995) . The pathway is regulated both at the level of substrate speci®city ± via the concerted actions of activating enzymes, carrier proteins and ligation enzymes ± and at the level of proteolytic deuibiquitation and ubiquitin hydrolysis. The latter enzymes are ubiquitin-speci®c thiol proteases which have been broadly classi®ed into two families: the ubiquitinspeci®c protease (UBPs) and the ubiquitin carboxyterminal hydrolases (UCHs).
The UBP family members are 50 ± 300 kDa, cytoplasmic or nuclear-localized proteins which, in general, cleave ubiquitin or ubiquitin-conjugates from large substrates. Such enzymatic activity can be found directly associated with the 26S proteasome and may serve a regulatory function by editing ubiquitin on large substrates or cleaving polyubiquitin, thus replenishing ubiquitin pools (Lam et al., 1997) . Remarkably, a number of UBPs have been isolated as growth regulatory and/or developmental control genes such as DOA4 in yeast, which controls DNA replication and repair (Papa and Hochstrasser, 1993) ; UBP3 which is involved in transcriptional silencing in yeast (Moazed and Johnson, 1996) ; the TRE2 oncogene which is mutated in the UBP active site and functions as a dominant negative transforming gene (Nakamura et al., 1992) ; the drosophila Fat Facets gene which controls pattern formation and eye development (Huang et al., 1995; Huang and FischerVize, 1996) ; and the human DUB family of cytokineinducible UBPs which control hematopoietic differentiation (Zhu et al., 1996 (Zhu et al., , 1997 .
By contrast, the UCH family has been characterized as a set of small (25 ± 30 kDa) cytoplasmic proteins which prefer to cleave ubiquitin from ubiquitinconjugated small substrates and may also be involved in the co-translational processing of proubiquitin. Like the UBPs, UCHs show considerable tissue speci®city and developmentally-timed regulation (Wilkinson et al., 1992) . UCH family members are dierentially expressed in neuronal, hematopoietic and germ cells in many species. Most remarkably, a novel UCH enzyme has recently been cloned from A. californica whose enzymatic function is essential for acquisition and maintenance of long-term memory (Hedge et al., 1997) . Finally, UCH levels are down-regulated during viral transformation of ®broblasts (Honore et al., 1991) , consistent with a role in growth control.
BAP1 is the newest member of the UCH family and considerably expands the potential roles of this family of proteases. BAP1 is a much larger protein (90 kDa) and is the ®rst nuclear-localized UCH. In addition to containing the *250 amino acid amino-terminal UCH catalytic domain, it includes a carboxy-terminal extension rich in proline, serine and threonine, and a short, highly acidic region; these elements may confer a short half-life upon the protein (Rechsteiner and Rogers, 1996) . The extreme carboxy-terminus encodes two potential nuclear localization signals that overlap the approximately 125 amino acid BRCA1-interaction domain. This domain is predicted to fold into a long amphiphatic helix of coiled-coil character, the structure of which may be important for BRCA1 interaction. Indeed, truncation into this region or substitution of a proline for leucine (L691P) abolish the BAP1 ± BRCA1 interaction in the two-hybrid assay. We have also detected a potential splice variant in BAP1 that results in loss of 31 amino acids of the BRCA1 interaction domain and greatly reduces the ability of BAP1 to bind the BRCA1 RING ®nger. Thus, our data suggest that the BAP1 carboxy-terminus is tethered to the BRCA1 RING ®nger domain, leaving the UCH catalytic domain free to interact with ubiquitinated, or other ubiquitin-like, substrates.
A simple model explaining most of our data is that BRCA1 is a direct substrate for the UCH activity of BAP1 and deubiquitination results in the stabilization of BRCA1. Thus, in contrast to the known UCHs which are comprised entirely of the UCH domain, the carboxy-terminal extension of BAP1 may provide substrate and/or targeting speci®city for the catalytic function. Paradigms for separate substrate recognition and catalytic domains occur throughout the ubiquitin conjugation/ligation system (see Wilkinson, 1995 and references therein) . Regulated ubiquitination of BRCA1 and subsequent proteasome-mediated degradation would be consistent with tight regulation of BRCA1 levels and its subnuclear localization during both the mitotic cell-cycle and meiosis (Gudas et al., 1996; Scully et al., 1997b; Zabludo et al., 1996) . Thus, BAP1-mediated deubiquitination of BRCA1 would stabilize the protein and protect it from proteasomemediated degradation. This scenario is consistent with both the ability of co-transfected BAP1 to enhance the tumor suppressor eects of BRCA1 in colony formation assays and the ®nding of mutations in BAP1 in cancer cell lines.
A second, and equally plausible hypothesis is that the BRCA1 ± BAP1 association serves to target the UCH domain to other substrates that may be bound to other sites on BRCA1. In this scenario, BRCA1 may function as an assembly or scaold molecule for regulated assembly of multiprotein complexes; a function that has been postulated for other tumor suppressor proteins (e.g. pRb; Sellers and Kaelin, 1996; Welch and Wang, 1995) . Thus, BAP1 could be a regulator of this assembly via its control of ubiquitinmediated proteolysis. Recently, it has been shown that the RING ®nger protein Ste5 (S. cerevisiae) functions as a scaold protein for assembling protein kinasedependent signaling complexes in pheromone signaling; this activity is abolished by mutations in the Ste5 RING ®nger (Inouye et al., 1997) . In this context, two other RING ®nger-containing proteins are involved in complexes whereby controlled proteolytic processes are dependent upon the integrity of the RING ®nger structure: (1) The murine homologue of the drosophila seven-in-absentia, siah, (a RING ®nger protein) binds to the tumor suppressor protein Deleted in Colon Cancer (DCC) and targets it for proteasome-mediated degradation. This degradation requires the siah RING ®nger structure (Hu et al., 1997) ; and (2) The herpesvirus protein VMW110 is a RING ®nger protein that binds directly to a UBP family member, HAUSP, and appears to target it to the ND10/POD nuclear dot structure. The ND10 structure itself contains another RING ®nger protein, the protooncogene PML (Everett et al., 1997) . Remarkably, the PML RING ®nger has been shown to bind and colocalize with a ubiquitin-like molecule PIC1/SUMO1 which is emerging as a central molecule in nuclearlocalized ubiquitin-dependent regulation (Saitoh et al., 1997) .
A third hypothesis is that BAP1 is involved in the regulation of protein subcellular localization. Monoubiquitination, or addition of a ubiquitin-like moiety, has emerged as an important post-translational modi®cation which may aect the speci®c targeting of proteins to locations other than the proteasome. For example, the addition of the ubiquitin-like PIC1/ SUMO1 protein appears to mediate the movement of RanGAP1 (a GTPase-activating protein) from the cytoplasm to the nuclear envelope where it binds the RanBP2 protein (Mahajan et al., 1997) . This interaction requires the ATP-dependent, covalent addition of PIC1/SUMO-1 to RanGAP1, a process extremely similar to the ATP-dependent, ubiquitin-ligation mechanism. Thus, BAP1-mediated removal of ubiquitin, or ubiquitin-like molecules, from BRCA1, or a protein associated with BRCA1, could target the complex to another cellular compartment, thus altering its function without physically destroying it. That BRCA1 is targeted to speci®c subcellular sites is evidenced by the observation that it accumulates in nuclear dot structures during S phase of the cell cycle. This localization is abolished at the S/G2 boundary (Scully et al., 1997b) .
The association of BRCA1 with RAD51 in both mitotic nuclear dot structures and meiotic cells broadly implicates BRCA1 in DNA repair and/or recombination processes. The RAD51/52-dependent DNA repair pathway is highly regulated and includes many proteins, some of which may be potential substrates for BAP1-mediated ubiquitin hydrolysis. RAD23, which associates with the RAD51/52 complex, contains an amino-terminal ubiquitin-like domain which is required for RAD23 function and double-strand break repair (Watkins et al., 1993) . Recently, a human ubiquitin-like protein, UBL-1, was isolated as a protein which binds directly to the human RAD51/RAD52 complex (Shen et al., 1996b) . Interestingly, the yeast homologue of UBL1 is SMT3, which functionally associates with the yeast centromere protein MIF2, a protein required for proper chromosome segregation (Brown, 1995; Brown et al., 1993) . Furthermore, the RAD51/52 complex contains a ubiquitin conjugating enzyme, hUBC9/ UBE2I (Jiang and Koltin, 1996; Shen et al., 1996a) . Thus, it appears that the DNA repair machinery contains both ubiquitin-conjugating and -hydrolyzing elements, since BAP1 is now implicated as a member of the BRCA1/RAD51/hUBC9 complex. It is possible that BAP1, which is co-expressed with BRCA1 in breast tissue, may regulate the recombination/repair functions of the BRCA1/RAD52 complex by targeting either RAD23 or UBL1 for ubiquitin hydrolysis.
The implications that BAP1 is a key regulator and/ or eector of BRCA1 suggest that BAP1 may also play a role in human cancer. The ®nding that BAP1 maps to human chromosome 3p21.3 strongly suggested this link; Loss of chromosome 3p genes is a critical event in lung cancer pathogenesis and other carcinomas. Interestingly, two other components of the ubiquitin metabolism pathway have been mapped to chromosome 3p21.3; an ubiquitin activating enzyme (Kok et al., 1993) and a ubiquitin protease, UNP (Gray et al., 1995) . The identi®cation of BAP1 as a UCH suggests a cluster of metabolically related enzymes at this locus. Furthermore, the frequent loss of this chromosomal region suggests that there may be a selective advantage for the loss of ubiquitinmediated cellular processes during carcinogenesis. That BAP1 may be included in this paradigm is suggested by our detection of rearrangements/deletions within BAP1 in lung cancers (this report) and our detection of independent, homozygous, point mutations in highly conserved residues of BAP1's enzymatic domain (Proctor et al., manuscript in preparation).
In summary, we have isolated a novel ubiquitin hydrolase which associates directly with the BRCA1 RING ®nger domain. BAP1 may play a key role in ubiquitin-dependent regulatory processes in the nucleus including transcription, chromatin remodeling, cell cycle control and DNA repair/recombination.
Materials and methods
Cell culture, transfections and colony formation assays All cells were grown at 378C and 5% CO 2 . COS1 and MCF7 cells were maintained in DMEM supplemented with 10% fetal bovine serum (FBS), L-glutamine and nonessential amino acids. Small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) cell lines were maintained in RPMI media with 10% fetal bovine serum (Gibco BRL). Rh30 cells were maintained in RPMI supplemented with 10% FBS and non-essential amino acids. COS1 cells were transfected using DOSPOR transfection reagent (Boehringer Mannheim Biochemicals) following the manufacturer's protocol.
Colony formation assay
MCF7 cells were transfected by a modi®ed CaPO 4 -DNA precipitation method (Holt et al., 1996) . MCF7 cells, at 2610 6 cells/10 cm dish, were fed fresh medium approximately 3 h prior to transfection, and were then treated with the Ca-DNA precipitate for 4 h. The cells were subjected to a brief shock with transfection buer containing 15% glycerol. Twelve to 16 h later, the cells were trypsinized, counted and plated directly into complete medium containing 0.75 mg/mL G418 at 5610 5 cells per 10 cm dish. Cells were fed fresh medium containing G418 every 3 ± 4 days. Cells were stained for colonies approximately 21 ± 28 days after transfection.
Yeast 2-hybrid
The yeast 2-hybrid system as modi®ed by Stan Hollenberg was used for all yeast experiments (Vojtek et al., 1993) . Two libraries were screened for interaction with LexA-BRCA1; a human B cell, oligo-dT-primed, cDNA library (Durfee et al., 1993) ; a kind gift from Dr Steve Elledge) and a mouse embryo (9.5 ± 10.5 day), random-primed, cDNA library size selected for inserts of 300 ± 500 base pairs in length (Vojtek et al., 1993) ; a kind gift of Dr Stan Hollenberg).
Construction of expression plasmids
LexA fusion constructs: The 100 amino acid terminal region of human BRCA1 (BRCA1-RF) was used as the bait to screen for interacting proteins. All LexA fusion constructs were made by cloning the appropriate RING (or other) domain into the vector pBTM-116 (Vojtek et al., 1993) . A synthetic gene of the BRCA1 ± RF domain was made from overlapping oligonucleotides whose codon usage had been optimized for expression in E. coli and S cerevisiae (Madden et al., 1991) . Double-stranded DNA was generated by the Polymerase Chain Reaction (PCR) and ampli®ed with¯anking primers containing EcoRI and SalI enzymatic restriction sites. A`wild type' BRCA1 ± RF domain was con®rmed by DNA sequencing. The single amino acid substitutions in the BRCA1 ± RF domain, BRCA1(C64G) (Cys 64 to Gly), BRCA1(C61G) (Cys 61 to Gly), BRCA1(M18T) (Met18Thr) and BRCA1(R71G) (Arg71 to Gly) as well as the BRCA1 ± delAG185 truncation mutant were created by PCR-mutagenesis (Ho et al., 1989) . The BRCA1-del31 truncation mutant was a mis-primed PCR reaction of the BRCA1 ± RF which was identi®ed by DNA sequencing. The LexA-RPT-1 protein (amino acids 1 ± 100) was made by PCR-mediated ampli®cation of the corresponding nucleotides of a RPT-1 PCR sample (Patarca et al., 1988) ; kindly provided by Dr Harvey Cantor). All clones were con®rmed by sequencing. Expression of all constructs in yeast was con®rmed by Western analysis using antibodies against the LexA DNAbinding domain (data not shown).
BAP1 constructs: A full-length BAP1 cDNA was assembled through the fusion of two overlapping EST clones (the IMAGE Consortium (LLNL); cDNA Clones #46154 and #40642; (Lennon et al., 1996) ) and the insertion of 62 nucleotides missing from clone #40642 (as revealed by sequencing and RT ± PCR analyses). GSThBAP1(483 ± 729) was generated by cloning the XhoI fragment of pAct (the original human two-hybrid clone; nucleotides 1486 ± 3525) into pGEX-5x-1 (Pharmacia Biotech, Inc.). GST-hBAP1(438 ± 594) and pACThBAP1(438 ± 594) (nucleotides 1486 ± 1821) were generated and ampli®ed by PCR, digested with restriction enzyme and ligated into the appropriate vector.
Mapping of BRCA1/BAP1 interaction domain
Truncations of mBAP(596 ± 721), and the point mutation mBAP1(L691P), were generated by PCR-based mutagenesis. Products were then ligated into the mouse libraryyeast expression vector, pVP16. All clones were con®rmed by sequencing and expression in yeast was con®rmed by Western analysis using antibodies against the VP16 activation domain (data not shown).
Northerns and in situ
Tissue RNA blots were obtained from Clontech Laboratories, Inc. (Palo Alto, CA). Blots were hybridized with 32 P-labeled hBAP1(483 ± 729) cDNA (nucleotides 1486 ± 3525) using standard protocols. RNA preparation, Northern hybridization of mouse mammary tissue, and in situ hybridization analyses were performed as previously described using the mouse Bap1 cDNA probe described by mBAP1(596 ± 721), corresponding to nucleotides 1825 ± 2202 of the human probe (Marquis et al., 1995) .
Fluorescent in situ hybridization (FISH)
FISH using a biotin-labeled 3.5 kb cDNA (full length) clone of BAP1, with corresponding DAPI-banding and measurement of the relative distance from the short arm telomere to the signals (FLpter value) was performed as described previously (Tommerup and Vissing, 1995) .
Immunolocalization
All immuno¯uorescence was performed as previously described (Ishov and Maul, 1996) . BAP1 protein was detected with anity puri®ed, BAP1-speci®c polyclonal antibodies, and BRCA1 was detected with the BR64 monoclonal antibody (Upstate Biotechnology), which were detected with FITC and Texas Red (respectively) using biotin-avidin enhancement. Cells were stained for DNA with bis-benzimide (Hoescht 33258, Sigma Chemical Co.) and mounted using Fluoromount G (Fisher Scienti®c). Analysis was performed with a confocal scanning microscope (Leica, Inc.).
BAP1 protein characterization
Generation of antibodies: Using PCR cloning, the cDNA region encoding amino acids 483 ± 576 of BAP1 was fused downstream of the six Histidine residues of the vector pQE-30 (QIAGEN Inc.). The His-tagged protein was puri®ed from E. coli over a Ni-agarose column as previously described (Friedman et al., 1996) and was used to immunize rabbits for the production of polyclonal antibodies (Cocalico Biologicals, Inc.). Immunoprecipitation of BAP1 was performed by previously described procedures for the metabolic labeling and immunoprecipitation of proteins from cell lysates (Friedman et al., 1996) .
In vitro protein association: GST, GST-hBAP1(483 ± 729) and GST-hBAP1(483 ± 594) were expressed in E. coli and then puri®ed as described (Frangioni and Neel, 1993) . The 35 S-BRCA1 protein was produced in vitro via coupled transcription/translation (TNT1, Promega Corp.). Association between proteins was assayed as described previously (Barlev et al., 1995) .
BAP1 enzymatic assay
Assays for BAP1 enzymatic activity were performed essentially as described for the UCH-L1 and UCH-L3 enzymes (Mayer and Wilkinson, 1989) . Brie¯y, bacteria harboring an IPTG-inducible expression plasmid containing BAP1 (pQE-30; QIAGEN Inc.) were grown and induced with 1 mM IPTG for 4 h. The bacteria were collected and the pellets were resuspended to 1/20 volume (original culture) in lysate buer (50 mM Tris, pH 8.0, 25 mM EDTA, 10 mM 2-mercapto-ethanol, 100 mg/ml lysozyme). The lysates were sonicated and centrifuged at 40 000 g. The soluble fractions were used for subsequent activity assays. The pellets were resuspended in a volume equal to that of the supernatant and samples of both pellet and supernatant were analysed by SDS ± PAGE for expression levels and inclusion body formation.
Assays for ubiquitin carboxy-terminal hydrolase activity were performed using the glycine 76 ethyl ester of ubiquitin (Ub-OEt) as substrate (Mayer and Wilkinson, 1989; Wilkinson et al., 1986) . Assays were done in triplicate. The peak areas were integrated and normalized with respect to a ubiquitin standard.
Mutation screening
RNA/DNA preparation: Genomic DNA was prepared from breast and lung cancer cell lines using standard methods. Total RNA was extracted by the cesium chlorideultracentrifugation method (Ausubel et al., 1987) . First strand cDNAs were synthesized from RNA by M-MLV reverse transcriptase (Gibco ± BRL) according to the manufacturer's instructions.
Southern and Northern blot hybridization: Five mg of genomic DNA, subjected to restriction enzyme digestion, or 10 mg total RNA, was electrophoretically gel-fractionated and transferred to Hybond N + membranes (Amersham). Hybridization was performed with a 32 P-full-length BAP1 cDNA probe followed by washes under standard conditions and detection by autoradiography.
Single strand conformational polymorphism (SSCP) analysis: Seventeen overlapping PCR primer pairs, each with a predicted product size of approximately 200 base pairs, were designed to span the 2.2 kb open reading frame of the BAP1 cDNA sequence. cDNA (from RNA) was ampli®ed in 20 ml PCR reactions containing 20 mM Tris HCl (pH 8.3), 50 mM KCl, 1.5 mM MgCl, 0.2 mM each dNTP, 0.1 mM each forward and reverse primer, 0.05 ml [ 32 Pa]dCTP and 0.5 units Taq DNA Polymerase (BRL). PCR reactions were carried out in a Perkin-Elmer 9600 Thermocycler using a touchdown technique: a 2.5 min initial denaturation at 948C was followed by 35 cycles of denaturation at 948C630 s, annealing, initially at 658C decreasing by 18C for each of the ®rst ten cycles to 558C, 630 s, and extension at 728C630 s with a ®nal extension of 5 min at 728C. PCR products were then diluted 1 : 10 with SSCP dye (95% formamide, 20 mM EDTA, and 0.05% each of bromophenol blue and xylene cyanol), heat-denatured, and electrophoresed on 0.56MDE gels +10% glycerol. Abnormal single stranded DNA detected as autoradiographic shifts were re-ampli®ed by PCR and subjected to automated dye-terminator sequencing (ABI 373).
